MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Merck & Co Inc.

Slēgts

SektorsVeselības aprūpe

79.89 1.46

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

76.03

Max

79.93

Galvenie mērījumi

By Trading Economics

Ienākumi

583M

3.7B

Pārdošana

-1B

16B

P/E

Sektora vidējais

11.55

57.333

EPS

1.72

Dividenžu ienesīgums

4.15

Peļņas marža

23.963

Darbinieki

73,000

EBITDA

1.3B

6.9B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+36.76% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

4.15%

2.63%

Nākamais dividenžu datums

2025. g. 7. jūl.

Nākamais Ex dividenžu datums

2025. g. 16. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-56B

196B

Iepriekšējā atvēršanas cena

78.43

Iepriekšējā slēgšanas cena

79.89

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Merck & Co Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. apr. 18:18 UTC

Galvenie tirgus virzītāji

Pharma Shares Reverse Losses After Tariff Pause

2025. g. 9. apr. 09:39 UTC

Galvenie tirgus virzītāji

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025. g. 4. febr. 12:33 UTC

Peļņas

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

2025. g. 4. febr. 11:57 UTC

Peļņas

Merck 4Q Sales Increase Results in Swing to Profit

2025. g. 24. apr. 20:08 UTC

Peļņas

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

2025. g. 24. apr. 16:05 UTC

Top Ziņas
Peļņas

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

2025. g. 24. apr. 14:36 UTC

Tirgus saruna
Peļņas

Merck's Challenges with Gardasil in China Continue -- Market Talk

2025. g. 24. apr. 14:10 UTC

Tirgus saruna
Peļņas

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

2025. g. 24. apr. 11:35 UTC

Peļņas

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

2025. g. 24. apr. 10:58 UTC

Top Ziņas
Peļņas

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

2025. g. 24. apr. 10:55 UTC

Peļņas

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

2025. g. 24. apr. 10:31 UTC

Peļņas

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Keytruda Sales $7.21B >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Pharmaceutical Sales $13.64B >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Keytruda Sales Up 4% >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Pharmaceutical Sales Down 3% >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

2025. g. 24. apr. 10:30 UTC

Peļņas

Merck 1Q Januvia/Janumet Sales $796M >MRK

2025. g. 24. apr. 09:13 UTC

Karstas akcijas

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

2025. g. 24. marts 05:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

2025. g. 5. marts 19:42 UTC

Top Ziņas

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

2025. g. 5. marts 10:30 UTC

Top Ziņas

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

2025. g. 5. febr. 12:00 UTC

Top Ziņas

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

2025. g. 4. febr. 14:48 UTC

Peļņas

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

2025. g. 4. febr. 11:51 UTC

Peļņas

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

2025. g. 4. febr. 11:50 UTC

Peļņas

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

2025. g. 4. febr. 11:31 UTC

Peļņas

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Salīdzinājums

Cenas izmaiņa

Merck & Co Inc. Prognoze

Cenas mērķis

By TipRanks

36.76% augšup

Prognoze 12 mēnešiem

Vidējais 108 USD  36.76%

Augstākais 138 USD

Zemākais 85 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Merck & Co Inc.  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

11

Pirkt

7

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

78.36 / 79.18Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.